EnPlusOne Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- EnPlusOne Biosciences's total funding is $22M.
Employee Data
- EnPlusOne Biosciences has 22 Employees.
- EnPlusOne Biosciences grew their employee count by 100% last year.
EnPlusOne Biosciences's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-founder, COO | Reveal Email/Phone |
2 | Associate Scientist I | Reveal Email/Phone |
3 | Associate Scientist II | Reveal Email/Phone |
4 | Lead RNA Synthesis | Reveal Email/Phone |
5 | Research Associate | Reveal Email/Phone |
6 | Senior Scientist | Reveal Email/Phone |
7 | Associate Researcher | Reveal Email/Phone |
8 | Scientist II | Reveal Email/Phone |
9 | Associate Scientist I | Reveal Email/Phone |
EnPlusOne Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 1 | -50% | N/A | N/A |
#3 | $5.1M | 33 | 22% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 2 | -60% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | N/A | 11 | 10% | N/A | N/A |
#10 | $5.4M | 29 | 0% | N/A | N/A |
What Is EnPlusOne Biosciences?
EnPlusOne is on a mission to bring RNA and RNA solutions to the world. Its ezRNA™ synthesis platform is a stepwise innovation that can incorporate a diverse array of nucleotide modifications and promises a manufacturing process that can sustainably deliver therapeutic RNA at commercial scales. In addition to direct RNA synthesis, EnPlusOne's ezRNA™ platform supports a vast array of RNA solution applications. For more information, please visit www.enplusonebio.com
keywords:N/A$22M
Total Funding
22
Number of Employees
N/A
Revenue (est)
100%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.4M | 22 | -4% | N/A |
#2 | N/A | 22 | -8% | N/A |
#3 | $4.1M | 23 | 10% | N/A |
#4 | $4.5M | 24 | 0% | N/A |
#5 | $4.7M | 24 | -4% | N/A |